Viropharma Extends Enterprise Contract with Medidata Solutions
Medidata Solutions
announced that Exton, Pa.-based ViroPharma Incorporated has extended its agreement to use the
Medidata Rave
electronic data capture (EDC) and clinical data management (CDM) platform for another multi-year period.
ViroPharma is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma currently focuses its drug development activities in diseases including hereditary angioedema (HAE), also known as C1 inhibitor deficiency and
C. difficile.
ViroPharma selected Rave initially in 2003 as an enterprise-wide EDC system based on its ability to handle large, complex, global studies and its collaboration-enabling data collection, management and reporting capabilities. Since then, ViroPharma has used Medidata Rave in all Phase I–IV clinical studies, covering a broad range of patients, countries and sites.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
